MacDonald, Amber F.
Bettaieb, Ahmed
Donohoe, Dallas R.
Alani, Dina S.
Han, Anna
Zhao, Yi
Whelan, Jay http://orcid.org/0000-0001-7804-9144
Funding for this research was provided by:
Tennessee Agricultural Experiment Station (TEN00441)
National Institutes of Health (R00DK100736)
Article History
Received: 1 February 2018
Accepted: 11 June 2018
First Online: 18 June 2018
Author’s information
: The impact of food and food components (including natural products) on delaying or inhibiting the promotion and progression of cancer and modifying the ability of relapse following the use standard therapies is the focus and line of research of the primary author (JW). If you are unfortunate enough to get an advanced form of prostate cancer (castrate-resistant prostate cancer), what can be done to enhance the effectiveness of standard therapies? This research focuses on castrate-resistant prostate cancer, a potentially deadly form of the disease, using an experimental design consistent with this condition to explore underlying mechanisms.
: Manuscripts reporting studies involving human participants, human data or human tissue must include a statement on ethics approval and consent (even where the need for approval was waived) and include the name of the ethics committee that approved the study and the committee’s reference number if appropriate.This research did not use any preclinical or animals models and did not involve human subjects. Therefore, this section is not applicable.
: This manuscript does not contains any individual person’s data (adult of child) in any form (including individual details, images or videos). Therefore, this section is not applicable.
: The authors have no conflicts of interest. They have not received any reimbursement fees or funding from the manufacturers or distributors of Zyflamend as outlined by the publisher. None of the authors hold stock or shares that can result in financial gain in anyway, nor have applied for patents or reimbursements or fees that would constitute a conflict of interest. The University of Tennessee Agricultural Experiment Station, the National Institutes for Health, the manufacturer of Zyflamend (New Chapter, Brattleboro, VT) or anyone affiliated with them, have not been consulted or associated with this study, or involved in the study design; in the collection, analysis, or interpretation of data; in the writing or review of the manuscript; or in the decision to submit the paper for publication. No financial support or product has been provided by New Chapter (Brattleboro, VT), manufacturer of Zyflamend, for this study. This research has been reviewed and accepted by all authors. It has not been published or submitted for publication elsewhere.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.